Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Pancreatic Cancer (Jul 2025)
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • Sex Differences in Medicine (Sep 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
OX40 signaling directly triggers the antitumor effects of NKT cells
Dapeng Zhou
Dapeng Zhou
Published November 1, 2007
Citation Information: J Clin Invest. 2007;117(11):3169-3172. https://doi.org/10.1172/JCI33976.
View: Text | PDF
Commentary Article has an altmetric score of 3

OX40 signaling directly triggers the antitumor effects of NKT cells

  • Text
  • PDF
Abstract

Pathways involving the costimulatory molecule OX40 and OX40 ligand (OX40L) enhance tumor rejection. It was presumed that this effect was mediated by changes in DCs and/or T cells. In this issue of the JCI, Zaini et al. report that, in mice, intratumoral injection of DCs genetically modified to express OX40L suppressed the growth of a preexisting melanoma by directly triggering an antitumor NKT cell response (see the related article beginning on page 3330). This work suggests that the intratumoral NKT cell population may be harnessed for cancer immunotherapy and that OX40 costimulation may be used as a unique trigger of the antitumor activity of these cells.

Authors

Dapeng Zhou

×

Figure 1

Crosstalk between OX40L-DCs and NKT cells.

Options: View larger image (or click on image) Download as PowerPoint
Crosstalk between OX40L-DCs and NKT cells.
It is hypothesized that OX40L...
It is hypothesized that OX40L-DCs first stimulate NKT cells (i) to proliferate and produce cytokines (ii). Subsequently, NKT cells activate DCs through cellular contacts (such as CD40/CD40L binding) and cytokine expression (iii), which induce the DCs to secret IL-12 and to upregulate costimulatory molecules such as CD80 and CD86. IL-12 stimulates the IL-12 receptor expressed by activated NKT cells (iv), which further potentiates NKT cell activation and forms a positive-feedback loop. Three lines of signaling transduction pathways are speculated to be activated in NKT cells: (a) TCR (Vα14 in mouse and Vα24 in human) signaling is assumed to be the first signaling pathway; (b) other costimulatory signaling networks such as CD28 might be involved and interact with both the TCR signaling network and the OX40 signaling network; and (c) OX40 signaling components may control the fate of NKT cells through molecular interactions with the TCR signaling network. OX40 interacts with TNF receptor–associated factors and may lead to the regulation of transcription factors such as NF-AT, NF-κB, and T-bet.

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts

Referenced in 1 patents
29 readers on Mendeley
See more details